Dermatology
Page 1 • 4 itemsAccess global dermatology market intelligence, drug development trends, and regulatory insights for pharma BD, investors, and analysts.
Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026
Sagimet Biosciences announces Phase 3 trial for denifanstat acne treatment starting H2 2026, while advancing TVB-3567 FASN inhibitor in Phase 1 studies.
Veradermics VDPHL01 Phase 2/3 Trial Results for Male Pattern Hair Loss to Be Announced
Veradermics announces investor call to discuss topline results from Phase 2/3 study of VDPHL01 for mild-to-moderate male pattern hair loss treatment.
Veradermics VDPHL01 Phase 2/3 Trial Results: Conference Call Scheduled for Oral Minoxidil Hair Loss Treatment
Veradermics announces investor call to discuss Phase 2/3 trial results for VDPHL01, an extended-release oral minoxidil tablet for male pattern hair loss.
Psoriasis Treatment Pipeline Explodes: 90+ Companies Race to Develop Next-Generation Therapies in 2026
Over 90 pharmaceutical companies are developing innovative psoriasis treatments, with promising therapies like Piclidenoson and Zasocitinib advancing through trials.